This approval was followed by Takeda Pharmaceuticals’ Alofisel (darvadstrocel), which received approval from the European Medicines Agency in 2018 and from Japan’s Pharmaceuticals and Medical Devices ...
The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...
Mirum Pharmaceuticals stock surged 25% and how LIVMARLI drives growth. Explore future prospects with Volixibat. Click here to ...
U.S. President Donald Trump said on Monday he will in the very near future announce tariffs on automobiles, aluminum and ...
The Patent Term Extension (PTE) provisions of 35 U.S.C. § 156 compensate pharmaceutical patent owners for time they are not ...
Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of novel peptide conjugate therapeutics for treating resp ...
Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of ...
MIRA Pharmaceuticals signs letter of intent to acquire SKNY Pharmaceuticals, adding SKNY-1, a preclinical drug for weight ...
22h
Victory Capital Management Inc. purchased a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback